Last reviewed · How we verify
Edaravone dexborneol sublingual tablet — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Edaravone dexborneol sublingual tablet (Edaravone dexborneol sublingual tablet) — Simcere Pharmaceutical Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Edaravone dexborneol sublingual tablet TARGET | Edaravone dexborneol sublingual tablet | Simcere Pharmaceutical Co., Ltd | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Edaravone dexborneol sublingual tablet CI watch — RSS
- Edaravone dexborneol sublingual tablet CI watch — Atom
- Edaravone dexborneol sublingual tablet CI watch — JSON
- Edaravone dexborneol sublingual tablet alone — RSS
Cite this brief
Drug Landscape (2026). Edaravone dexborneol sublingual tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/edaravone-dexborneol-sublingual-tablet. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab